Clinical Trial Update: MSP3-CRM-Vac4All/ Alhydrogel® Vaccine [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update for the MSP3-CRM-Vac4All/Alhydrogel vaccine addressing malaria caused by Plasmodium falciparum.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria
• Plasmodium Falciparum Malaria

Drugs mentioned

• MSP3-CRM-Vac4All/Alhydrogel vaccine (MSP3-CRM-Vac4All with Alhydrogel)

Snippet

Sponsor: Vac4All | Conditions: Malaria,Falciparum | Phase 1, Phase 2 | Status: UNKNOWN